84-9362-43　Recombinant Human RANKL/TNFSF11 Protein （Active） 50ug　PKSH031027

特徴

• 背景：Tumor necrosis factor ligand superfamily member 11, also known as Receptor activator of nuclear factor kappa-B ligand, Osteoprotegerin ligand, TNFSF11, RANKL, TRANCE, OPGL and CD254, is a single-pass type II membrane protein which belongs to the tumor necrosis factor family.
• The receptor activator of nuclear factor-kappaB ligand （RANKL）, its cognate receptor RANK, and its natural decoy receptor osteoprotegerin have been identified as the final effector molecules of osteoclastic bone resorption.
• RANK and RANKL are key regulators of bone remodeling and regulate T cell/dendritic cell communications, and lymph node formation.
• Moreover, RANKL and RANK are expressed in mammary gland epithelial cells and control the development of a lactating mammary gland during pregnancy.
• Genetically, RANKL and RANK are essential for the development and activation of osteoclasts and bone loss in response to virtually all triggers tested.
• Inhibition of RANKL function via the natural decoy receptor osteoprotegerin （OPG, TNFRSF11B） prevents bone loss in postmenopausal osteoporosis and cancer metastases.
• Importantly, RANKL appears to be the pathogenetic principle that causes bone and cartilage destruction in arthritis.
• RANK-RANKL signaling not only activates a variety of downstream signaling pathways required for osteoclast development, but crosstalk with other signaling pathways also fine-tunes bone homeostasis both in normal physiology and disease.
• In addition, RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy.